Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8DOC

Crystal structure of RPE65 in complex with compound 16e and palmitate

Summary for 8DOC
Entry DOI10.2210/pdb8doc/pdb
DescriptorRetinoid isomerohydrolase, FE (II) ION, 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID, ... (6 entities in total)
Functional Keywords7-bladed beta propeller, monotopic membrane protein, non-heme iron enzyme, retinoid isomerase, inhibitor, complex, hydrolase
Biological sourceBos taurus (cattle)
Total number of polymer chains1
Total formula weight61746.03
Authors
Bassetto, M.,Kiser, P.D. (deposition date: 2022-07-12, release date: 2023-05-24, Last modification date: 2024-11-06)
Primary citationBassetto, M.,Zaluski, J.,Li, B.,Zhang, J.,Badiee, M.,Kiser, P.D.,Tochtrop, G.P.
Tuning the Metabolic Stability of Visual Cycle Modulators through Modification of an RPE65 Recognition Motif.
J.Med.Chem., 66:8140-8158, 2023
Cited by
PubMed Abstract: In the eye, the isomerization of all--retinal to 11--retinal is accomplished by a metabolic pathway termed the visual cycle that is critical for vision. RPE65 is the essential - isomerase of this pathway. Emixustat, a retinoid-mimetic RPE65 inhibitor, was developed as a therapeutic visual cycle modulator and used for the treatment of retinopathies. However, pharmacokinetic liabilities limit its further development including: (1) metabolic deamination of the γ-amino-α-aryl alcohol, which mediates targeted RPE65 inhibition, and (2) unwanted long-lasting RPE65 inhibition. We sought to address these issues by more broadly defining the structure-activity relationships of the RPE65 recognition motif via the synthesis of a family of novel derivatives, which were tested and for RPE65 inhibition. We identified a potent secondary amine derivative with resistance to deamination and preserved RPE65 inhibitory activity. Our data provide insights into activity-preserving modifications of the emixustat molecule that can be employed to tune its pharmacological properties.
PubMed: 37279401
DOI: 10.1021/acs.jmedchem.3c00461
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

237992

数据于2025-06-25公开中

PDB statisticsPDBj update infoContact PDBjnumon